WEST LAFAYETTE, Ind. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today that it intends to offer and sell shares of its common stock in an underwritten registered public
– Patrick Machado , Co-founder and Former Chief Business and Financial Officer of Medivation, Brings Significant Experience in Building Value in the Prostate Cancer Space – WEST LAFAYETTE, Ind. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing
– Phase 3 VISION Trial Design Finalized for 177 Lu-PSMA-617 Following Successful End of Phase 2 Meeting with the FDA – – Announced Agreement for Clinical Supply of No-Carrier-Added Lutetium with ITM – – Added Experienced Clinical Trial Professionals to Support Execution of
WEST LAFAYETTE, Ind. and MUNICH, Germany, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced a supply agreement under which ITM will supply to Endocyte the medical radioisotope
West Lafayette, Ind. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Feb. 26th , at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
WEST LAFAYETTE, Ind. , Dec. 15, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI).
WEST LAFAYETTE, Ind. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company's management team will present at the Jefferies 2017 London Healthcare Conference
- Plans to Initiate Phase 3 Registration for 177 Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte - - The University of Sydney and ANZUP Cancer Trial Group Set to Initiate Trial of 177 Lu-PSMA-617 versus
WEST LAFAYETTE, Ind. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Nov. 6th , at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update.
- Transformational Transaction Provides Endocyte with the Most Advanced Targeted Radioligand Therapy in Development for Prostate Cancer, Addressing a Greater than $1 Billion Market Opportunity - - High Response Rates Demonstrated in Late Stage Prostate Cancer Patients in Clinical Data Presented at
